Please login to the form below
OAB
This page shows the latest OAB news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding
Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... hMaxi-K has been evaluated in two phase I studies in OAB patients including a small phase Ib clinical
Latest news
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB patients with benign prostatic hyperplasia, plus a third trial in patients with
-
Germany’s IQWiG denies Astellas’ incontinence drug
OAB). This review will be taken into consideration by the Federal Joint Committee (GBA), which will then recommend on whether the drug should be reimbursed on Germany's healthcare system. ... The decision is in contrast to the positive guidance from the
-
Astellas uses animated bladder in campaign
The campaign is for overactive bladder (OAB) drug Myrbetriq shows an untreated bladder character constantly interrupting a woman as she goes about her daily activities (see video above or on YouTube). ... The new campaign is aimed at women aged 45-69
-
Astellas gets first OK for prostate drug Vesomni
Urology is a core product franchise for Astellas, with its standalone Harnal (tamsulosin) product for BPH and overactive bladder (OAB) therapy Vesicare (solifenacin) bringing in sales of 67bn yen and 87bn ... The company has already added to its OAB
-
Allergan gets US approval for Botox in overactive bladder
OAB caused by neuronal damage, for example as a result of spinal cord injury or multiple sclerosis. ... OAB is a condition in which the bladder squeezes too often or squeezes without warning, leading to urinary incontinence, sudden urgent need to urinate
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Astellas: Ten years young
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new ... class of OAB treatments to emerge in over 30 years, the
-
Interview: Kay Drake and Naoki Okamura, Astellas
For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
-
Show stopper exposes taboo
Nearly one in five people in the UK over 40 have an overactive bladder (OAB) and live with the urgent need to go to the toilet. ... The campaign therefore needed to encourage people to set aside embarrassment, speak up about OAB and seek help.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Astellas strengthens US and Canadian leadership team
As Sabus leaves from the US, Astellas has promoted Lynn Fenicchia Gerber (pictured left) to US vice president, primary care, where she will lead sales efforts for the OAB, anti-fungal,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
emotive project Decisions in Time wins gold for the Digital solution for congress/symposium at the 2014 PM Digital Media Awards
Other emotive projects OAB Health Economics won silver in the Craft Award – Mobile and Diabetes Voyager won bronze in the Innovation Award – Pushing Boundaries. ... To get more details about Decisions in Time, OAB Health Economics,
-
Award-winning emotive project, Decisions in Time, nominated as a finalist in yet more pharmaceutical awards
Along with emotive projects like Diabetes Voyager and OAB Health Economics and Neil Kumar being nominated for Account Manager of the Year, emotive is a finalist for a total of six
-
emotive client Adam Boucher of Novo Nordisk announced as a finalist for Digital Pioneer at the 2014 PM Digital Awards
OAB Health Economics app has been nominated in the Craft Award – Mobile category. -
-
Neil Kumar announced as a finalist for Account Manager of the Year at the PM Society Digital Media Awards 2014
Decisions in Time and the OAB Health Economics app.
-
emotive is thrilled to be a sponsor of the PM Society’s Digital Media Awards 2014
Craft Award – Mobile for OAB Health Economics.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Featured jobs
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
-
Health Consultant - Brand Comms
-
Competitive Salary
- Scientific Director – Medical Communications
-
Salary TBC
-
Digital Account Director
-
Salary TBC
- Senior Account Manager, Medical Communications, London
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
Subscribe to our email news alerts
- Blood disorder specialists Imara raises $63m
- NICE wants to stop saying ‘no’ – but needs pharma’s co-operation
- Three questions that should anchor your brand strategy
- Allergy Tx hit hard as birch pollen product stumbles
- Sanofi gets cardio outcomes claim for Praluent in EU
- Keytruda adds another NSCLC approval in Europe
PMHub
Hayward Medical Communications
Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...
Latest intelligence
- “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
- The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
- The Future of Pharma sales: fast forward to 2029
- Change is inevitable, and necessary, for growth in business....
- International Women's Day - 8 March 2019
- International Women's Day has been celebrated since its inception in 1911. But how far have we come?...
Quick links
Infographics
